|
Lorus advances clinical development of GTI-2040 combined with Ara-c in acute myeloid leukemia |
|
|
|
30 Aug 2007 |
Expanded clinical program supported by promising results from completed trial
TORONTO, Canada | August 29, 2007 | Lorus Therapeutics Inc. (“Lorus”) (TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced completion of a proof of concept clinical trial in Acute Myeloid Leukemia (AML), and expansion of its GTI-2040 development program in this indication, with initiation of a more advanced Phase II clinical trial with GTI-2040 and high dose Ara-C (HiDAC) in refractory and relapsed AML.
The advanced Phase II clinical trial, which is now underway includes both an efficacy study and a novel additional study to measure intracellular target activities and pharmacological synergies between the two agents. In the first stage of the 60 patient trial, the pharmacologic and target related activity of GTI-2040 and HiDAC will be evaluated in two groups, to determine the contribution of each agent alone and in combination. The second stage of the trial will provide efficacy evaluation in a larger patient population. Lorus expects the clinical trial to be completed by the end of 2008.
The decision by Lorus to advance clinical development of GTI-2040 is based on the encouraging results from our recently completed proof of concept study of GTI-2040 in combination with HiDAC in patients with refractory and relapsed AML. This clinical trial demonstrated safety and appropriate dosing of the combination regimen and showed promising clinical responses in patients under 60 years of age. Moreover, the clinical responses correlated with downregulation of R2, the cellular target of GTI-2040, and were further supported by demonstration of intracellular GTI-2040 in circulating and bone marrow leukemic cells. Complete results from the clinical trial are expected to be presented by the investigators in a scientific publication.
“The initiation of an advanced Phase II clinical trial with GTI-2040 is a very significant step forward for Lorus, and for the development of its clinical stage pipeline. This underscores the dedication of Lorus’ clinical and regulatory teams to the development of novel anticancer agents”, commented Dr. Aiping Young, President & CEO of Lorus. “The clinical data for GTI-2040 in AML are consistent with an antisense mode of action, and the frequency of responses and statistical correlation of this with target activity are very encouraging. We believe that this drug will provide an important new treatment opportunity for AML patients.”
This new advanced Phase II clinical trial is sponsored by Lorus and is being led by Dr. Rebecca Klisovic as Principal Investigator and Dr. Guido Marcucci as co-investigator, at The Comprehensive Cancer Center of Ohio State University. Dr. Marcucci was also the Principal Investigator on the previous clinical trial of GTI-2040 in AML, which was carried out with the sponsorship of the Cancer Therapy Evaluation Program of the US National Cancer Institute. Dr. Marcucci and his team at OSU have extensive experience with antisense and other targeted therapies in leukemic indications and in genetic studies of leukemia
SOURCE: Lorus Therapeutics |
